TorreyPines Therapeutics (NASDAQ: TPTX) has announced its strategic plan for 2008. Unfortunately it doesn’t look or sound very promising. The company will focus on clinical development activities to maximize the value of the company’s…
The venture backers and the officers and insiders Genoptix (NASDAQ: GXDX) have filed to sell 4.2 million shares of common stock in a secondary offering, which could be up to 4.83 million shares of…
Heparin, made Baxter International (NYSE: BAX) is one of the most widely used blood thinners in the world. Today’s disclosure that the U.S. Food and Drug Administration said it never inspected a Chinese facility…
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) has just filed a shelf registration that would allow the company to sell up to $75 million in securities. The offering can be in stock, debt, warrants, or…
CNBC’s Mike Huckman just announced what is going to be a disappointment for Dendreon (NASDAQ: DNDN) holders, and that may be an understatement. The House Committee will not be forcing any action or pressing…
The bad days never seem to end at Boston Scientific (NYSE: BSX). The company has a heavy debt load from a bad acquisition of Guidant. The BSX stent business has been hurt by studies…
Teva Pharmaceuticals (NASDAQ: TEVA) posted earnings at $0.69 EPS on revenues of $2.58 Billion; First Call had consensus at $0.66 EPS on $2.48 Billion in revenues. There are some big numbers ahead for Teva…
Discovery Laboratories Inc. (NASDAQ: DSCO) shares are up after a report that their drug Surfaxin, a respiratory distress syndrome treatment for premature infants, should gain FDA approval by May. In pre-market trading, the shares…
Below are some of the news items affecting shares of biotech stocks: Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) is enjoying upgrades after a positive earnings release Thursday. The company’s partnership with Swiss drug maker Roche…
Icagen Inc. (NASDAQ: ICGN) has announced that it has provided notice to exercise its put option with Pfizer Inc. (NYE: PFE). This is for the private placement of approximately $10 million of Icagen common…
The default rate on junk bonds in 2007 was well under 1%. Junk guru and finance professor Edward Altman says that number will move well above 4.6% this year. According to The Wall Street…
On Wednesday, we’ll get to see earnings out of Biogen Idec Inc. (NASDAQ: BIIB). The estimates from First Call for the biotech company are $0.80 EPS on $835.16 million in revenues. Estimates for fiscal…
Below are some of the top issues affecting biotech shares today: AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company developing iron compounds to treat anemia, saw shares rise 4% to $56.00 after brokerage firm…
On Tuesday morning, we’ll get to see earnings out of Boston Scientific Corp. (NYSE:BSX). The estimates from First Call for the medical device developer are $0.09 EPS on $2.13 billion in revenues. Estimates for…
Medtronic, Inc. (NYSE: MDT) has just announced that it has received formal approval from the FDA to market its Endeavor Zotarolimus-Eluting Coronary Stent System for the treatment of coronary artery disease. This had been…